Conference on FY2025
(April 1, 2025 to March 31, 2026)
Financial Results

Toru Kimura, President and CEO

Sumitomo Pharma Co., Ltd.

May 13, 2026

Sumitomo Pharma
Innovation today, healthier tomorrows

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties.

Accordingly, due to various subsequent factors, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and other products (including those under development) contained herein is not intended as advertising or as medical advice.

Financial Results for FY2025

Financial Results for FY2025 (Core Basis)

Billions of JPY

	FY2024 Results	FY2025 Results	Change			FY2025
			Value	FX impact	%	Mar. 2 forecasts
Revenue	398.8	**453.3**	54.5	(5.3)	13.7	449.0
Cost of sales	153.2	**196.4**	43.2	(0.9)	28.2	
Gross profit	245.6	**256.9**	11.2	(4.4)	4.6	
SG&A expenses	167.7	**159.3**	(8.4)	(1.4)	(5.0)	
R&D expenses	48.5	**43.9**	(4.5)	(0.4)	(9.4)	
Others (core basis)	13.7	**52.3**	38.6			
Core operating profit	43.2	**105.9**	62.8	(2.6)	145.4	107.0
Adjustment items (negative number indicates net expense)	(14.3)	**1.4**	15.8			
Operating profit	28.8	**107.3**	78.5		272.6	108.0
Finance income/costs	(11.2)	**(7.0)**	4.2			
Profit before taxes	17.6	**100.3**	82.7		469.8	
Income tax expenses	(6.0)	**(6.5)**	(0.5)			
Net profit attributable to owners of the parent	23.6	**106.9**	83.2		352.2	102.0

Average rates:
FY2024 Results : 1US$ = ¥152.62, 1RMB = ¥21.11
FY2025 Results : 1US$ = ¥150.67, 1RMB = ¥20.12
FY2025 forecasts : 1US$ = ¥150.00, 1RMB = ¥20.12

Period end rates:
As of the end of March 2025 : 1US$ = ¥149.53, 1RMB = ¥20.59
As of the end of March 2026 : 1US$ = ¥159.90, 1RMB = ¥20.74

- Revenue increased primarily due to the growth of ORGOVYX® and GEMTESA® and sales milestone revenue from ORGOVYX®
- SG&A expenses and R&D expenses decreased due to business structure improvements, partial transfer of the Asian business, and realignment of the regenerative medicine and cell therapy business
- Others (core basis)
  FY2024: Gain on transfer of the regenerative medicine and cell therapy business
  FY2025: Gain on partial transfer of the Asian business +¥49.0B
- Adjustment items:
  FY2024: Business structure improvement expenses in Japan and North America

Revenue of Major Products in North America

	FY2024 Results	FY2025 Results	Change	FY2024 Results	FY2025 Results	Change		
						Value	FX impact	%
North America	Millions of USD			Billions of JPY				
ORGOVYX®	544	**1,029**	484	83.1	**155.0**	71.9	(2.0)	86.6
MYFEMBREE®	84	**96**	12	12.8	**14.4**	1.6	(0.2)	12.6
GEMTESA®	431	**637**	206	65.8	**96.0**	30.2	(1.2)	46.0
RETHYMIC®	45	**42**	(3)	6.8	**6.3**	(0.5)	(0.0)	(7.1)
APTIOM®	258	**99**	(159)	39.4	**14.9**	(24.5)	(0.2)	(62.1)
Others	80	**56**	(24)	12.2	**8.0**	(4.2)	(0.1)	(34.3)
Export products/ One-time revenue, etc.*	208	**287**	78	31.8	**43.3**	11.5	(0.7)	36.1
Total	1,650	**2,245**	595	251.8	**337.9**	86.1	(4.5)	34.2

- ORGOVYX® and GEMTESA® revenue increased significantly year-on-year
- APTIOM® revenue decreased due to loss of exclusivity
- Sales milestone revenue from ORGOVYX® has been recognized

* Major items included in Export products/One-time revenue, etc.

FY2024 Results	Deferred revenue from the collaboration with Pfizer	$171M	FY2025 Results	Deferred revenue from the collaboration with Pfizer	$88M
				Sales milestone revenue from ORGOVYX® (sales exceeding $500M)	$100M

Average rates:
FY2024 Results : 1US$ = ¥152.62
FY2025 Results : 1US$ = ¥150.67

Revenue of Major Products in Japan

Billions of JPY

	FY2024 Results	FY2025 Results	Change	
			Value	%
Japan				
LATUDA®	13.2	**13.7**	0.5	4.1
TWYMEEG®	7.6	**10.6**	3.0	39.0
METGLUCO®	7.3	**7.4**	0.1	1.3
Equa®/EquMet®	24.9	**8.7**	(16.2)	(64.9)
LONASEN® Tape	4.6	**5.0**	0.4	8.2
XEPLION®/XEPLION TRI®	—	**3.2**	3.2	—
AG products	11.4	**12.1**	0.7	5.9
Others	22.9	**22.6**	(0.3)	(1.4)
Export products/ One-time revenue, etc.	7.9	**9.0**	1.1	14.4
Total	99.8	**92.4**	(7.5)	(7.5)

Note: Sales of each product are shown by invoice price

- TWYMEEG® revenue continued to grow
- Equa®/EquMet® revenue decreased due to loss of exclusivity (discontinued in Dec. 2025)
- XEPLION®/XEPLION TRI® transitioned to in-house distribution in January

Financial Forecasts for FY2026

Boost Toward “Strong Sumitomo Pharma”

Achieved a V-shaped recovery through fundamental structural reforms. By further revenue growth of ORGOVYX® and GEMTESA® and the development of next-generation growth engines, we are now entering a phase of Boost toward “Strong Sumitomo Pharma.”

Delay in adjusting scale and deterioration of PL

- Overestimation of the potential of acquired products
- Development failure of new drug candidates
- LOE of LATUDA®

Rebuilding the Value Creation Cycle
Reboot 2027

1. Implementation of fundamental structural reforms
   - Streamlining, selection and concentration
   - Revision of R&D investment strategy
2. Expansion of revenues for the 3 key products*

From “Value Creation” to “Value Delivery”
Boost 2028

1. Further revenue expansion of ORGOVYX® and GEMTESA®
2. Fastest possible market launch of the two oncology compounds
3. Developing next-generation growth engines
4. Strengthening our financial base

Sumitomo Pharma

* ORGOVYX®, GEMTESA® and MYFEMBREE®

Allocation to Investment in Medium- to Long-Term Growth, Balanced with Financial Discipline and Based on Sound Financial Foundations

Sound Financial Foundation

	Before Financial Restructuring	**Financial Restructuring** (Equity Financing and Refinancing)	**After** Financial Restructuring
Debt	Financial constraints Debt guarantees Subordinated debt	Decision to release debt guarantees through refinancing Defined pathway toward replacement of subordinated debt	Borrowings without debt guarantees Increased borrowing capacity for investment in growth
Equity	Low equity ratio	Achieved record-high earnings Executed a public equity offering	Improved equity ratio

R&D Investment

FY2026 forecast: JPY 51 billion

Key initiatives

- Fastest possible launch and value expansion of two oncology assets
- Development of next-generation revenue bases (CNS and infectious diseases)

Capital Expenditure / Investments and Loans

FY2026 forecast: JPY 12 billion

Key initiatives

- Strengthening of existing businesses (production capabilities, quality management systems, etc.)
- Investments and loans to RACTHERA and S-RACMO

Shareholder Returns

FY2026 outlook: undetermined

Decision based on future business performance

Key decision factors

- Cash flow
- Financial condition, including equity ratio

Change in Reportable Segments (from FY2026)

- **Previously, operating segments were disclosed by region based on the entity recording sales. Reflecting our globally integrated operations, we have adopted a single Pharmaceuticals segment.**

(Former reportable segments)
- Regional segments (Japan/North America/Asia)

(New reportable segment)
- Single Pharmaceuticals segment

- **Regional information will continue to be disclosed based on the markets rather than the entity recording sales.**

Until FY2025		
Segment	**Consolidated selling entity**	**Market**
Japan	Sumitomo Pharma Sumitomo Pharma Promo	Japan
		Ex-Japan
North America	SMPA（Sumitomo Pharma America, Inc.） SMPS（Sumitomo Pharma Switzerland GmbH）	U.S.
		Ex-U.S.
Asia	Asian subsidiaries (until July, 2025) Product Supply to Marubeni Global Pharma (from August, 2025)	Asia

From FY2026	
Segment	**Market**
Pharmaceuticals	**Japan**
	U.S.
	Other

The change in segmentation has no impact on consolidated financial results.

Financial Forecasts for FY2026 (Core Basis)

Billions of JPY

	FY2025 Results	FY2026 Forecasts	Change		
			Value	FX impact	%
Revenue	453.3	**540.0**	86.7	12.2	19.1
Cost of sales	196.4	**245.0**	48.6	3.5	24.7
Gross profit	256.9	**295.0**	38.1	8.7	14.8
SG&A expenses	159.3	**155.0**	(4.3)	3.4	(2.7)
R&D expenses	43.9	**51.0**	7.1	0.9	16.0
Others (core basis)	52.3	**2.0**	(50.3)		(96.2)
Core operating profit	105.9	**91.0**	(14.9)	4.4	(14.1)
Adjustments (negative number indicates loss)	1.4	**(1.0)**	(2.4)		
Operating profit	107.3	**90.0**	(17.3)		(16.2)
Finance income/costs	(7.0)	**(6.5)**	0.5		
Income tax expenses	(6.5)	**6.5**	13.0		
Net profit attributable to owners of the parent	106.9	**77.0**	(29.9)		(27.9)
ROE*	46.3%	**20.3%**			
ROIC*	22.8%	**15.1%**			

* FY2026 forecasts reflect the completed public offering and planned debt repayment.

- **Revenue:**
  U.S. + ¥84.6B :
  Continued growth of ORGOVYX® and GEMTESA®, incorporating ORGOVYX® sales milestone revenue
- **Cost of sales:**
  Incorporates a certain level of risk related to tariffs and inflation
- **SG&A expenses:**
  Decrease, despite unfavorable FX impacts
- **R&D expenses:**
  Accelerating development of oncology products and advancing CNS programs
- **Others (core basis):**
  Gain from the partial transfer of Asian business in the prior year

Average rates:
FY2025 Results : 1US$ = ¥150.67, 1RMB = ¥20.12
FY2026 Forecasts : 1US$ = ¥155.00

Sumitomo Pharma

Financial Forecasts for FY2026

Core Operating Profit Bridge FY25 vs FY26

Billions of JPY



Financial Forecasts for FY2026

Revenue of Major Products in U.S.

	FY2025 Results	FY2026 Forecasts	Change	FY2025 Results	FY2026 Forecasts	Change		
						Value	FX impact	%
U.S.	Millions of USD			Billions of JPY				
ORGOVYX®	1,029	**1,354**	325	155.0	**209.9**	54.9	5.9	35.4
MYFEMBREE®	96	**100**	4	14.4	**15.4**	1.0	0.4	7.3
GEMTESA®	637	**686**	49	96.0	**106.3**	10.3	3.0	10.7
RETHYMIC®	42	**35**	(7)	6.3	**5.4**	(0.9)	0.1	(14.2)
APTIOM®	99	**35**	(64)	14.9	**5.4**	(9.5)	0.2	(63.6)
Others *	234	**412**	178	35.2	**63.9**	28.7	2.2	81.7
Total	2,137	**2,622**	485	321.8	**406.4**	84.6	11.8	26.3

- ORGOVYX® and GEMTESA® revenue are expected to increase significantly
- APTIOM® revenue is expected to decline due to the impact of generic products
- Sales milestone for ORGOVYX® is expected in FY2026

* Major items included in Others

FY2025 Results	Deferred revenue from the collaboration with Pfizer	$88M	FY2026 Forecasts	Deferred revenue from the collaboration with Pfizer	$65M
	Sales milestone revenue from ORGOVYX® (sales exceeding $500M)	$100M		Sales milestone revenue from ORGOVYX® (sales exceeding $1.0B)	$325M

FX rates:
FY2025 Results : 1US$ = ¥150.67
FY2026 Forecasts : 1US$ = ¥155.00

Financial Forecasts for FY2026

ORGOVYX®

FY2025 Performance

FY2025 Initial Forecast	FY2025 Results	Year-over-year comparison
$710M	**$1,029M** **(Achievement: 145%)**	**Approx.** **89% Increase**

- Volume: Nearly doubled compared to last year and significantly outperformed the initial forecast by $260M, driven by changes in the Medicare Part D patient Out of Pocket Costs. NPS*1 in March reached a record high
- Price: Outperformed the initial forecast by $32M due to favorable payer mix and lower usage of coupon

Note: Achieved revised forecast ($1,020M)

FY2026 Forecast ($M)



Note: Forecast represents product sales only and does not include sales milestone

Commercial Strategy

Further expand market share through continued growth in urology and enhanced engagement with oncologists

- **Maximize growth in key segments, such as urology and radiation oncology,** by emphasizing clinical benefits, enhancing engagement with key medical congresses, and executing strategic initiatives for scale up through GPOs*2
- **Accelerate adoption in oncology where opportunity exists** by strengthening promotion, enhancing engagement with key medical congresses, peer-to-peer initiatives, and DTC*3 advertising
- **Capitalize on improvements in access and patient affordability** through raising awareness of patient out-of-pocket costs among HCPs, payers, and patients

*1: New Patient Start *2: Group Purchasing Organizations *3: Direct to Consumer

Financial Forecasts for FY2026

GEMTESA®

FY2025 Performance

FY2025 Initial Forecast	FY2025 Results	Year-over-year comparison
$572M	**$637M** **(Achievement: 111%)**	**Approx.** **48%** **Increase**

- Volume: Exceeded the initial forecast by $27M due to the steady growth of demand and share in expanding β3 market by clinical differentiation
- Price: Outperformed the initial forecast by $40M due to favorable payer mix

Note: Overachieved revised forecast ($588M)

FY2026 Forecast ($M)



Commercial Strategy

Continue to focus on growing GEMTESA® market share through emphasis on GEMTESA® clinical differentiation and improved coverage in Medicare part D

- **Elevate OAB*1 treatment expectations** by amplifying GEMTESA® strong efficacy and safety profile via online education to HCPs and direct to patient initiatives, leveraging patient ambassadors' program
- **Solidify conviction for GEMTESA® clinical differentiation** with an elevated promotional focus on patients with hypertension and men with OAB and BPH*2
- **Strengthen the perception of the access of GEMTESA®** through strong and broad promotion of updated coverage status

*1: Overactive bladder *2: Benign Prostatic Hyperplasia

Financial Forecasts for FY2026

GEMTESA®

FY2025

- ✓ As a result of strategic negotiations with payers, coverage in major insurance plans declined, and pricing (GTN*1) temporarily improved
- ✓ During this period, demand remained solid, leading to the resumption of coverage by some insurance plans

FY2026

- ✓ Pricing (GTN) is expected to decline due to factors such as the full-year impact of coverage resumption and Inflation Reduction Act (IRA) *2
- ✓ Meanwhile, **demand is growing strongly, supported by improved patient access, and progress is being made toward achieving sales of JPY 150 billion in the 2030s.**

Variance Analysis: Previous Years vs FY2026 Forecast ($M)



Number of Prescription by Fiscal Years*3



*1. GTN (Gross-to-Net): An adjustment rate calculated by subtracting rebates, discounts, deductions, etc., from gross sales.
*2. The Inflation Reduction Act (IRA) lowered the out-of-pocket patient payment limit for Medicare Part D and also changed the phases and percentages of the burden borne by pharmaceutical companies. Small manufacturers are given a gradual grace period for the application of these changes.
*3: Information licensed from IQVIA (NPA for the period April 1, 2021 to March 31, 2026, reflecting estimates of real-world activity). All rights reserved.

Gross Profit by Region (Core Basis)

Billions of JPY

		Japan	U.S.	Other	Total
FY2026 Forecast	Revenue	87.6	406.4	46.0	540.0
	Cost of sales	52.1	152.7	40.2	245.0
	Gross profit	35.5	253.7	5.8	295.0
FY2025 Results	Revenue	83.4	321.8	48.1	453.3
	Cost of sales	43.7	123.2	29.5	196.4
	Gross profit	39.6	198.7	18.6	256.9
Change	Revenue	4.2	84.6	(2.1)	86.7
	Cost of sales	8.4	29.5	10.7	48.6
	Gross profit	(4.1)	55.0	(12.8)	38.1

Japan
- XEPLION®/XEPLION TRI® contribute to increasing revenue, but gross profit decreases due to the product mix.

U.S.
- Gross profit increases due to increased revenue.

Other
- Profit decreases due to the partial transfer of the Asian business.

Research and Development

Research and Development

Development Pipeline (As of May 13, 2026)

Revisions since the announcement in January 2026 are shown in red

Area	Generic Name/Product Code	Mechanism of Action, etc.	Planned Indication(s)	Development Stage
Psychiatry & Neurology	DSP-0038	Serotonin 5-HT_{2A} receptor antagonist and serotonin 5-HT_{1A} receptor agonist	Alzheimer's disease psychosis	Phase 1
	DSP-0187	Selective orexin-2 receptor agonist	Narcolepsy	Phase 1
	DSP-3456	Metabotropic glutamate receptor 2/3 negative allosteric modulator (mGluR2/3 NAM)	Treatment resistant depression	Phase 1
	DSP-0378	Gamma-aminobutyric acid (GABA) $_A$ receptor positive allosteric modulator	Progressive Myoclonic Epilepsy Developmental Epileptic Encephalopathy	Phase 1
	DSP-2342	Serotonin 5-HT_{2A} and 5-HT_7 receptor antagonist	To be determined	Phase 1
	DSP-0551	Multi-ion channel modulator	Tremor associated with Parkinson's disease	Phase 1
	CT1-DAP001/DSP-1083 (Japan)	Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells	Parkinson's disease	Conditional and time-limited approval obtained (Mar 2026) ⇒ Post-marketing clinical study in preparation
	CT1-DAP001/DSP-1083 (U.S.)	Allogeneic iPS cell-derived dopaminergic neural progenitor cells	Parkinson's disease/Investigator-initiated study, Company- sponsored clinical study	Phase 1/2
	HLCR011(Japan)	Allogeneic iPS cell-derived retinal pigment epithelial cells	Retinal pigment epithelium tear	Phase 1/2
	DSP-3077(U.S.)	Allogeneic iPS cell-derived retinal sheet	Retinitis pigmentosa	Phase 1/2
Oncology	Enzomenib	Selective menin inhibitor	Acute leukemia	Phase 2
	Nuvisertib	PIM1 kinase inhibitor	Myelofibrosis	Phase 1/2
	SMP-3124	CHK1 inhibitor	Solid tumors	Phase 1/2
	DSP-0390	EBP inhibitor	Glioblastoma	Phase 1
Others	KSP-1007	β-lactamase inhibitor	Complicated urinary tract and intraabdominal infections, Hospital-acquired bacterial pneumonia	Phase 1
	fH1/DSP-0546LP	Split, Adjuvanted vaccine	Influenza virus prophylaxis	Phase 1

Major Topics in Clinical Development (January 31– May 13, 2026)

Psychiatry & Neurology

Allogeneic iPS cell-derived dopaminergic neural progenitor cells (U.S., Japan) (collaboration with RACTHERA)

- Parkinson's disease
  In March 2026, obtained conditional and time-limited approval in Japan (product name: AMCHEPRY®)
  The proposed NHI reimbursement price is scheduled to be discussed at the Central Social Insurance Medical Council meeting on May 13
  Post-marketing clinical study to be initiated in 2026 (see page 21 for details)

Allogeneic iPS cell-derived retinal sheet (DSP-3077) (U.S.) (collaboration with RACTHERA)

- Retinitis pigmentosa
  In March 2026, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for retinitis pigmentosa

Lurasidone (Japan)

- Schizophrenia (product name: LATUDA®)
  In Japan, submitted a partial change application to add pediatric dosage and administration for the treatment of schizophrenia

DSP-0551 (Japan)

- Tremor associated with Parkinson's disease
  Initiation of a Phase 1 study (see page 22 for details)

DSP-0378 (Japan)

- Progressive myoclonic epilepsy / Developmental epileptic encephalopathy
  Initiation of Phase 1 studies (multiple-dose and drug–drug interaction studies), and initiation of dosing in the Phase 1b study

Major Topics in Clinical Development (January 31– May 13, 2026)

Oncology

Enzomenib (U.S., Japan)

- Initiation of a Phase 1 study in patients with newly diagnosed acute leukemia (KMT2A rearrangement or NPM1 mutation), in combination with VEN/AZA＊1 or 7+3＊2

Nuvisertib (U.S., Japan)

- In June 2026, plan to present interim data from a Phase 1/2 study in combination with momelotinib at the European Hematology Association (EHA); the abstract was published on May 12, 2026

Others

fH1/DSP-0546LP: universal influenza vaccine candidate

- Publication of interim analysis data from a Phase 1 study (cross-reactivity against influenza A virus subtypes) (see page 23 for details)

＊1 Ven: Venetoclax / Aza: Azacitidine ＊2 7+3: Standard induction chemotherapy commonly used for newly diagnosed acute leukemia

AMCHEPRY® Post-marketing Clinical Study (Phase 4 Study)

- ✓ Planned study initiation: In 2026 (7 clinical sites planned; details under discussion)
- ✓ Planned enrollment: 30 patients (ages 18–65), then 5 patients (ages > 65)
  - ☐ 2026–2029: Transplantation limited to patients enrolled in the Phase 4 study
  - ☐ After completion of the Phase 4 study: Gradual expansion to additional sites and patient population



Introduction of a Novel Compound: DSP-0551

- ✓ Target: Tremor associated with Parkinson's disease
- ✓ Origin: In-house (identified through phenotype-based drug discovery)
- ✓ Mechanism of action: Multi-ion channel modulator
- ✓ Development stage: Phase 1 (Japan)

(Expected timing for results: Q2 FY2027)

- ✓ Expected profile:
  - ➢ This compound inhibits multiple calcium channels and sodium channels that have been implicated in tremor-related pathophysiology
  - ➢ In nonclinical studies, the compound demonstrated strong efficacy across multiple tremor models and a wide safety margin, and is expected to become a novel therapeutic option for tremor associated with Parkinson's disease

Tremor-related neural circuitry



Modulation of tremor-related neural circuitry, expected to improve tremor

Infectious diseases areas: fH1/DSP-0546LP universal influenza vaccine (UIV) candidate

The formulation utilizing the company's proprietary TLR7 adjuvant technology platform

Interim analysis of a Phase 1 clinical study: Cross-reactivity to multiple Influenza A virus subtypes*1

The constantly mutating Influenza A virus



Group 1

H1N1 subtype

- Circulates annually as a seasonal influenza virus
- Has caused major outbreaks in 1918 (Spanish flu), 1977 (Russian flu), and 2009 (pandemic)

H5N1 subtype

- Also known as a highly pathogenic avian influenza virus, with expanding infections in a wide range of animal species
- First confirmed to infect humans in 1997, and human infection often results in severe disease

Group 2

H3N2 subtype

- Circulates annually as a seasonal influenza virus
- Pandemic in 1968 (Hong Kong flu)

Phylogenetic tree of influenza A subtypes (hemagglutinin)



Induction of antibodies against LAH*2

Geometric mean±95% confidence interval（n=12）
fH1 antigen 8μg＋DSP-0546LP 5μg



*1:The ability to elicit broad immune responses against different viral subtypes, which is a defining characteristic of a universal vaccine
*2: One of the conserved, cryptic antigenic regions shared among a wide range of influenza viruses

Key Development Products: Major Scheduled Milestones in FY2026 (as of May 13, 2026)

Area	Program	Q1	Q2	Q3	Q4	Remarks
Psychiatry & Neurology	DSP-0378 (Progressive Myoclonic Epilepsy Developmental Epileptic Encephalopathy)				Initial PoC*1 acquisition	
	CT1-DAP001 / DSP-1083 (Parkinson's disease)			(Japan) First transplantation*2		*2 Post-marketing clinical study
	DSP-3077 (Retinitis pigmentosa)		(U.S.) First transplantation*3			*3 Phase 1/2
Oncology	Enzomenib (Monotherapy, relapsed or refractory KMT2A-rearranged Acute Leukemia)	Phase 2 Completion of enrollment for interim analysis		Phase 2 Interim analysis Top-line results		NDA filing (Q1 FY2027)
	Enzomenib (Monotherapy, relapsed or refractory NPM1-mutated Acute Myeloid Leukemia)	Phase 2 Enrollment initiation			Phase 2 Completion of enrollment for interim analysis	
	Nuvisertib (Combination with momelotinib, newly diagnosed and relapsed or refractory Myelofibrosis)			Phase 3 Decision on recommended dose*4		*4 To be determined in consultation with the FDA
	SMP-3124 (Monotherapy, solid tumors)				Phase 2 Decision on recommended dose*4	
Others	fh1 / DSP-0546LP (Universal Influenza Vaccine)		Final analysis of 1-year follow-up*5		CHIS*6 study Initiation	*5 One-year follow-up safety data, antibody persistence, and subtype specific immune response analyses (e.g., IgG2, IgG4)

＊1 Initial PoC (Proof of Concept): Preliminary confirmation of efficacy in patients based on a limited number of cases ＊6 Controlled Human Infection Studies: Human challenge studies

Appendix

＜Contents＞

Financial Results for FY2025 (Full Basis)

Billions of JPY

	FY2024 Results	FY2025 Results	Change	
			Value	%
Revenue	398.8	453.3	54.5	13.7
Cost of sales	153.4	196.4	43.0	28.0
Gross profit	245.4	256.9	11.5	4.7
SG&A expenses	180.6	162.6	(18.0)	(10.0)
R&D expenses	49.9	44.0	(5.9)	(11.8)
Other operating income and expenses	13.9	57.0	43.1	
Operating profit	28.8	107.3	78.5	272.6
Finance income and costs	(11.2)	(7.0)	4.2	
Profit before taxes	17.6	100.3	82.7	469.8
Income tax expenses	(6.0)	(6.5)	(0.5)	
Net profit attributable to owners of the parent	23.6	106.9	83.2	352.2

Financial Position and Cash Flow

Billions of JPY

B / S	As of March 2025	As of March 2026	Change
Assets	742.6	804.6	62.0
Other non-current assets	28.2	64.4	36.2
Trade and other receivables	74.8	131.4	56.6
Assets held for sale	30.4	0.0	(30.4)
Liabilities	573.1	512.1	(61.0)
Bonds and borrowings	305.4	217.2	(88.2)
Deferred tax liabilities	26.6	15.8	(10.7)
Provisions	72.0	89.6	17.6
Liabilities directly associated with assets held for sale	3.5	0.0	(3.5)
Equity	169.5	292.5	123.0
Attributable to owners of the parent	169.5	292.5	123.0
(Ratio of equity attributable to owners of the parent to total assets)	22.8%	36.4%	

C / F	FY2024	FY2025	Change
Operating CF	16.5	71.7	55.2
Investment CF	99.8	22.5	(77.2)
Financial CF	(108.8)	(91.3)	17.6
Cash and cash equivalents at beginning of year	29.0	23.1	(5.9)
Cash and cash equivalents at end of period	23.1	44.3	21.2

Increase in investments accounted for using the equity method

Increase in accounts receivable due to sales growth, etc.

Repayment of borrowings

Reversal of deferred tax liabilities due to assignment of intangible assets within our group

Increase in provisions due to sales growth, etc.

FY24: Sales of investment securities
FY25: Proceeds from loss of control of subsidiaries

FY24: Repayment of borrowings
FY25: Repayment of borrowings

Segment Information (Core Basis)

Billions of JPY

		Japan	North America	Asia	Total
FY2025 Results	Revenue	92.4	337.9	23.0	453.3
	Cost of sales	50.1	137.4	8.8	196.4
	Gross profit	42.2	200.5	14.2	256.9
	SG&A expenses	29.9	124.7	4.7	159.3
	Core segment profit	12.4	75.7	9.5	97.5
	R&D expenses				43.9
	Core operating profit				105.9
FY2024 Results	Revenue	99.8	251.8	47.2	398.8
	Cost of sales	51.8	90.8	10.6	153.2
	Gross profit	48.0	161.0	36.6	245.6
	SG&A expenses	36.6	118.4	12.7	167.7
	Core segment profit	11.4	42.6	23.9	77.9
	R&D expenses				48.5
	Core operating profit				43.2
Change	Revenue	(7.5)	86.1	(24.2)	54.5
	SG&A expenses	(6.7)	6.3	(8.0)	(8.4)
	Core segment profit	0.9	33.1	(14.5)	19.6
	R&D expenses				(4.5)
	Core operating profit				62.8

Japan

- Despite the decline of gross profit due to lower revenue, core segment profit increased due to SG&A expense reduction

North America

- Core segment profit increased significantly due to revenue-driven growth in gross profit

Asia

- Core segment profit decreased due to the partial transfer of the Asian business

Prescription Trends of GEMTESA®

- The total number of GEMTESA® prescriptions and new prescriptions continued to increase despite the launch of Mirabegron generics in Apr. 2024

TRx



NBRx



Source: Based on information licensed from IQVIA: NPA for the period 4/1, 2022 to 3/31, 2026 reflecting estimates of real-world activity. All rights reserved.

Appendix (Financial Forecasts for FY2026)

Revenue of Major Products in Japan

Billions of JPY

	FY2025 Results	FY2026 Forecasts	Change	
			Value	%
Japan				
XEPLION®/XEPLION TRI®	3.2	**17.1**	13.9	431.7
LATUDA®	13.7	**13.6**	(0.1)	(0.8)
TWYMEEG®	10.6	**11.9**	1.3	12.5
METGLUCO®	7.4	**7.6**	0.2	2.9
Equa®/EquMet®	8.7	**—**	(8.7)	—
AG products	12.1	**11.2**	(0.9)	(7.5)
Others	27.6	**26.2**	(1.4)	(5.2)
Total	83.4	**87.6**	4.2	5.1

- Sales of XEPLION®/XEPLION TRI® recorded throughout the year
- Continued focus on driving growth of TWYMEEG®
- Return of Equa®/EquMet® distribution rights

Note: Sales of each product are shown by invoice price

AMCHEPRY® Schedule up to the First Transplantation (Planned)

Following reimbursement approval, we are advancing site-level activities, including Institutional Review Board (IRB) submissions, contract execution, and site activation

FY2025	FY2026								
March	April	May	June	July	August	September	October	November	December

Revisions since the announcement in January 2026 are shown in red

Main Events / Targets for FY2025 (as of May 13, 2026)

Psychiatry & Neurology	☑ Allogeneic iPS cell-derived products (Parkinson's disease: AMCHEPRY®); Obtain approval in Japan ⇒Conditional and time-limited approval (Mar 2026) ☑ Allogeneic iPS cell-derived products (Parkinson's disease): Advance Phase 1/2 study in the U.S. ☐ Allogeneic iPS cell-derived products (Retinal pigment epithelium tear): Start the randomized portion of the Phase 1/2 study in Japan ☐ Allogeneic iPS cell-derived products (Retinitis pigmentosa): Achieve clinical administration in the U.S.
Oncology	☐ Enzomenib : Completion of patient enrollment for Phase 2 study ☑ Nuvisertib : Advance Phase 1/2 study (monotherapy or in combination with JAK inhibitors) ☑ SMP-3124: Advance Phase 1/2 study ☑ Advance development of early-stage compounds
Others	☑ Advance Phase 1 studies of universal influenza vaccine ☑ Advance development of early-stage compounds

Appendix (Research and Development)

Product Launch Target (as of May 13, 2026)

Revisions since the announcement in January 2026 are shown in red

Psychiatry & Neurology　Oncology



* Relapsed or refractory acute leukemia with KMT2A rearrangement or acute myeloid leukemia with NPM1 mutation

Appendix (Research and Development)

Revisions since the announcement in January 2026 are shown in red

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA Co., Ltd.) (as of May 13, 2026)

Brand name/Cell type Product code	Indications	JP/ US	Pre-clinical	Clinical research	Phase 1/2	Phase 3	Approval application	Approval→ Launch
RETHYMIC®	Congenital athymia	US						
Dopaminergic neural progenitor cells (Allo iPS cell-derived) CT1-DAP001/DSP-1083	Parkinson's disease	JP US			4 5			1 Conditional and time-limited approval obtained (Mar 2026)
Retinal pigment epithelial cells (Allo iPS cell-derived) HLCR011	Retinal pigment epithelium tear	JP			5			
Retinal sheet (3D retinal tissue) (Allo iPS cell-derived) DSP-3077	Retinitis pigmentosa	JP US		2	5			
Neural progenitor cells (Allo iPS cell-derived)	Spinal cord injury	JP US		3				
Nephron progenitor cells (organ) (Auto/ Allo iPS cell-based induced)	Kidney failure	JP/ US						

1. Kyoto University Hospital 2. Kobe City Eye Hospital 3. Keio University Hospital
4. University of California San Diego School of Medicine 5. Company-sponsored clinical study


Sumitomo Pharma
Innovation today, healthier tomorrows